Rein Therapeutics

RNTX

Market cap $77M

AUSTIN, Texas, July 21, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics, Inc. ("Rein" or the "Company") (NASDAQ: RNTX), a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class medicines for orphan pulmonary and fibrosis indications, today announced that its Phase 2 RENEW clinical trial is now open and enrolling patients across all five planned countries, with Germany joining the United States, United Kingdom, Australia, and Poland.

Rein Therapeutics Inc. (RNTX) Shareholder/Analyst Call Prepared Remarks Transcript

Rein Therapeutics Inc. (RNTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

16 patients enrolled to date in trial of LTI-03 in idiopathic pulmonary fibrosis (IPF) First patient randomized in the United Kingdom Clinical trial sites now actively enrolling in the United States, Australia, and the United Kingdom Two additional countries expected to be added in the coming months AUSTIN, Texas, June 11, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics, Inc. ("Rein" or the "Company") (NASDAQ: RNTX), a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class medicines for orphan pulmonary and fibrosis indications, today provided an update on its ongoing Phase 2 RENEW clinical trial evaluating LTI-03 in patients with idiopathic pulmonary fibrosis (IPF). The Company announced that the first patient has been randomized in the United Kingdom, marking another milestone in the ongoing expansion of the Phase 2 RENEW clinical trial.

Total gross proceeds increased to $57.5 million Offering consisted solely of common stock Proceeds expected to fund Phase 2 trial of LTI-03 in IPF through completion and support operations into 2028 AUSTIN, Texas, May 18, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics, Inc. ("Rein" or the "Company") (NASDAQ: RNTX), a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class medicines for orphan pulmonary and fibrosis indications, today announced the closing of its previously announced underwritten public offering of common stock, including the full exercise of the underwriters' over-allotment option. The financing included new and existing healthcare-focused investors, including Adar1 Capital Management LLC, Ikarian Capital LLC, Bios Partners, Stonepine Capital Management, Cable Car Capital LP, and Second Line Capital.

AUSTIN, Texas, April 30, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics, Inc. ("Rein" or the "Company") (NASDAQ: RNTX), a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class medicines for orphan pulmonary and fibrosis indications, today announced the pricing of its underwritten public offering of fifty million shares of its common stock at a public offering price of $1.00 per share for aggregate gross proceeds of $50 million, prior to deducting underwriting discounts and commissions and other offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 7.5M shares of common stock at the public offering price per share, less the underwriting discounts and commissions, to cover over-allotments, if any. The offering is expected to close on or about May 4, 2026, subject to the satisfaction of customary closing conditions. The offering consisted entirely of common stock with no warrants.

Patient enrollment accelerates across expanding number of clinical trial sites in multiple countries 8 patients enrolled, with additional patients expected in the near term Enrollment initiated in March 2026, with patients being added on a regular basis Clinical trial sites active in the United States, Australia, and Poland, with additional countries expected to open in the near term AUSTIN, Texas, April 29, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today provided an update on its ongoing Phase 2 RENEW clinical trial evaluating LTI-03 for the treatment of idiopathic pulmonary fibrosis (IPF). The Company has enrolled 8 patients in its RENEW trial to date, with 2 additional patients expected to be enrolled this week.

Rein Therapeutics (NASDAQ:RNTX) stock is trading higher on Monday, with a session volume of 41.2 million compared to its average volume of 162.67 thousand, according to data from Benzinga Pro.

AUSTIN, Texas, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that it has received authorization from the European Medicines Agency (EMA) to initiate the Company's Phase 2 “RENEW” clinical trial of its lead candidate, LTI-03, for the treatment of idiopathic pulmonary fibrosis (IPF).

AUSTIN, Texas, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced the publication of novel data on its lead drug candidate, LTI-03, in iScience, a peer-reviewed, open-access journal published by Cell Press.